Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2016 - 2024)

Historic Preferred Stock Liabilities for Spyre Therapeutics (SYRE) over the last 4 years, with Q1 2024 value amounting to $253.4 million.

  • Spyre Therapeutics' Preferred Stock Liabilities changed N/A to $253.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $253.4 million, marking a year-over-year change of. This contributed to the annual value of $84.6 million for FY2023, which is N/A changed from last year.
  • As of Q1 2024, Spyre Therapeutics' Preferred Stock Liabilities stood at $253.4 million.
  • Spyre Therapeutics' Preferred Stock Liabilities' 5-year high stood at $387.1 million during Q3 2023, with a 5-year trough of $84.6 million in Q4 2023.